Study to Assess Hemodynamic Effects, Safety and Tolerability of Chimeric Natriuretic Peptide (CD-NP) in Patients With Stabilized Acute Heart Failure (AHF)

Key Inclusion Criteria: * Hospitalization for AHF * In need of hemodynamic monitoring Key Exclusion Criteria: * Administration of intravenous radiographic contrast agent within 7 days prior to screening or planned IV contrast media administration in the 4 days after screening or acute contrast-induced nephropathy at the time of screening * Current or planned treatment with any IV therapies, including diuretics, vasodilators (including nesiritide), vasopressin antagonists, positive inotropic agents and vasopressors, or mechanical support * Current or planned ultrafiltration, hemofiltration, or dialysis within 7 days of screening * Significant pulmonary disease * Known valvular heart disease * Any organ transplant recipient or patient currently listed for transplant or admitted for any transplantation. * Major surgery within 30 days of screening * Other major disability or disease with expected survival less than 6 months. * Major neurologic event, including cerebrovascular events, in the 60 days prior to screening * Clinical diagnosis of acute coronary syndrome within 45 days of screening * Troponin T ≥ 3 times the upper limit of normal at screening * Significant arrhythmias * Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy * Liver function abnormality * Administration of an investigational drug or implantation of investigational device, or participation in another trial, within 30 days prior to screening